Search results
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance· 6 days agoBristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you...
Smart Money Is Betting Big In BMY Options - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 5 days agoLoading... Loading... Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb . Looking at options history for Bristol-Myers Squibb BMY we detected ...
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
Morningstar· 6 days agoBy Denny Jacob Bristol Myers Squibb disclosed that the U.S. Food and Drug Administration granted accelerated approval of Augtyro. The biopharmaceutical product developer said the approval is based on results from a Phase 1/2 study which
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Motley Fool via Yahoo Finance· 4 days agoThe S&P 500 is up an incredible 25% over the past 12 months, but not every stock in the benchmark...
Gateway - Quartz
Quartz· 1 day agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar drug that dominates a market, brings in hordes of customers, and deposits hefty profits in ...
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade |...
The Motley Fool· 4 days agoThe S&P 500 is up an incredible 25% over the past 12 months, but not every stock in the benchmark...
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
Zacks via Yahoo Finance· 5 days agoThe FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric...
EU regulator mandates label updates on CAR-T cancer therapies
Reuters via AOL· 5 days agoThe European Medicines Agency's (EMA) mandate, which echoes the one issued by the U.S. health...
M&A Is Back. 4 Stocks That Could Be Targets.
Barrons.com· 5 hours agoMergers are back—and that means opportunity for small-cap investors. The return of M&A has been helped along by a number of factors, including a...
New JAK 1 Inhibitor Proves Promising in Phase 3 RA Trial
Medscape· 6 hours agoThe highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients...
